Cedarburg Acquires InB: Hauser Pharmaceutical Services.

-- Acquisition creates a leader in Contract Development and Manufacturing --

GRAFTON, Wis. -- Cedarburg Pharmaceuticals, Inc. ("Cedarburg") -- a privately owned chemistry-based Contract Development Manufacturing Organization ("CDMO") specializing in the production of Active Pharmaceutical Ingredients (API's) and key intermediates for the pharmaceutical and biopharmaceutical industries announced today its acquisition of InB: Hauser Pharmaceutical Services ("Hauser"). The acquisition further strengthens Cedarburg's position as a leader in the rapidly growing CDMO market and leverages the trusted reputation and synergistic capabilities of both companies to offer clients a more fully-integrated manufacturing platform strategically focused on helping client's move new chemical entities (NCE's) to market.

Hauser's expertise in natural products, isolation/ purification and cGMP manufacturing augment Cedarburg's synthetic chemistry and cGMP manufacturing expertise and effectively broadens the overall service capabilities offered to clients. The acquisition expands Cedarburg's extensive inventory of unit operations and comprehensive analytical instrumentation to include NMR and MALS and further amplifies Cedarburg's toll manufacturing capabilities for the production of API's and key intermediates.

The newly formed company called -Cedarburg Hauser Pharmaceuticals, Inc., will offer customers a broad range of best-in-class pharmaceutical services to meet the development and production needs of its clients. Both companies offer a combined 34-year history working in the pharmaceutical industry, proven turn-key cGMP compliance systems, and seasoned professionals specialized in providing highly customized process and analytical chemistry from the bench through commercial production.

With over 70,000 + square feet of multi-purpose US-based FDA-registered facilities (process development laboratories, kilo and commercial scale manufacturing suites, analytical and microbiology laboratories, stability and material sample storage) the combined operations will focus on the following specialty areas:

* Highly customized NCE's requiring complex chemistry

* Cytotoxic & Potent API's

* Naturally Derived & Semi-Synthetic API's

* Controlled Substances 

* Commercial cGMP API manufacturing

* High-Value Dietary Supplements and Cosmetics (ACI's)

"The acquisition allows us to maximize the true potential of both organizations as one fully integrated contract development and manufacturing organization building value for our shareholders, employees, and customers. The merger will also speed up the development and manufacturing of products currently in our product pipeline," said R. Anthony (Tony) Laughrey, President and CEO of Cedarburg. "The new Cedarburg Hauser is well positioned to provide increased efficiency for our clients as they move their critical process development and manufacturing projects through clinical development and ultimately into the commercial arena," Mr. Laughrey continued.

About Cedarburg Pharmaceuticals

Cedarburg Pharmaceuticals is a value-driven commercial and clinical API provider. We define value as making life simpler for our customers. That means understanding our customers' needs and exceeding their expectations through transparent project management and resourcefully applying our expertise in process development, validation, Scale-Up and analytical method development. Backed by full cGMP compliance and QA oversight, our experience and flexibility enable us to succeed where others fail. For more information, please visit us online at www.cedarburgpharma.com.

About InB: Hauser Pharmaceutical Services

Hauser is a contract development manufacturing organization (CDMO) dedicated to providing excellent service, high-quality actives and key intermediates to the pharmaceutical and biopharmaceutical industries. Hauser offers an established, completely integrated platform proven to quickly and efficiently move our client's products to market. Over the last 25-years Hauser has actively developed, scaled and optimized hundreds of unique chemical processes and analytical methods for our clients, starting from the pre-clinical stage to commercial production (mg -to-multi-hundred kilos) under strict cGMP guidelines, in our US-based facilities. Hauser's specialties include cytotoxics, next-generation chemotherapeutics, multi-step custom synthesis, naturally derived actives, and complex separation projects.

Forward Looking Statement

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.